BRPI0409405A - compostos 7-aza-quinazolina substituìdos - Google Patents

compostos 7-aza-quinazolina substituìdos

Info

Publication number
BRPI0409405A
BRPI0409405A BRPI0409405-0A BRPI0409405A BRPI0409405A BR PI0409405 A BRPI0409405 A BR PI0409405A BR PI0409405 A BRPI0409405 A BR PI0409405A BR PI0409405 A BRPI0409405 A BR PI0409405A
Authority
BR
Brazil
Prior art keywords
aza
substituted
quinazoline compounds
compounds
quinazoline
Prior art date
Application number
BRPI0409405-0A
Other languages
English (en)
Inventor
Nolan James Dewdney
David Michael Goldstein
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0409405A publication Critical patent/BRPI0409405A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

"COMPOSTOS 7-AZA-QUINAZOLINA SUBSTITUìDOS". A presente invenção refere-se a compostos de Fórmula (I) ou (II) onde R, R6, R7 e Q são como indicados no relatório descritivo. Os compostos são de utilidade como inibidores de p38 quinase, podendo ser usados no tratamento de distúrbio mediado por p38.
BRPI0409405-0A 2003-04-16 2004-04-13 compostos 7-aza-quinazolina substituìdos BRPI0409405A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46322903P 2003-04-16 2003-04-16
PCT/EP2004/003883 WO2004091625A1 (en) 2003-04-16 2004-04-13 (6-(phenoxy)-pyrido`3,4-d! pyrimidin-2-yl)-amine derivatives as p38 kinase inhibitors for the treatment of inflammatoryy conditions such as rheumatois artritis

Publications (1)

Publication Number Publication Date
BRPI0409405A true BRPI0409405A (pt) 2006-04-25

Family

ID=33300055

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409405-0A BRPI0409405A (pt) 2003-04-16 2004-04-13 compostos 7-aza-quinazolina substituìdos

Country Status (16)

Country Link
US (2) US7189731B2 (pt)
EP (1) EP1620105B1 (pt)
JP (1) JP2006523640A (pt)
KR (1) KR20060006037A (pt)
CN (1) CN1774250A (pt)
AR (1) AR044515A1 (pt)
AU (1) AU2004229163A1 (pt)
BR (1) BRPI0409405A (pt)
CA (1) CA2520785A1 (pt)
CL (1) CL2004000805A1 (pt)
DE (1) DE602004004259T2 (pt)
ES (1) ES2279361T3 (pt)
MX (1) MXPA05010975A (pt)
RU (1) RU2005135329A (pt)
TW (1) TW200503722A (pt)
WO (1) WO2004091625A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004020908A1 (de) * 2004-04-28 2005-11-17 Grünenthal GmbH Substituierte 5,6,7,8,-Tetrahydro-pyrido[4,3-d]pyrimidin-2-yl- und 5,6,7,8,-Tetrahydro-chinazolin-2-yl-Verbindungen
WO2006056863A1 (en) * 2004-11-23 2006-06-01 Ranbaxy Laboratories Limited Pyrido’2, 3-d!pyrimidines as anti-inflammatory agents
ES2303758B1 (es) * 2006-02-20 2009-08-13 Laboratorios Almirall S.A. Nuevos derivados de piridin-3-amina.
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
MX2011009034A (es) 2009-03-11 2011-09-22 Auckland Uniservices Ltd Formas de profarmaco de inhibidores de cinasa y su uso en la terapia.
EP2473509A4 (en) 2009-09-02 2013-04-17 Auckland Uniservices Ltd KINASEHEMMER, PRODRUG-FORMS THEREOF AND ITS USE IN THERAPY
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
LT3691620T (lt) 2017-10-05 2022-09-26 Fulcrum Therapeutics, Inc. P38 kinazės inhibitoriai, sumažinantys dux4 ir pasrovinių genų raišką, skirti fshd gydymui

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1199768A (en) * 1966-10-31 1970-07-22 Pfizer & Co C Nitrogen Heterocycles and process for their preparation
JPS4936700A (pt) * 1972-08-16 1974-04-05
US4672116A (en) * 1985-12-20 1987-06-09 Ortho Pharmaceutical Corporation Substituted 5,6-dialkoxyquinazoline derivatives
US5084463A (en) * 1989-12-11 1992-01-28 American Home Products Corporation N-quinolinyl alkyl-substituted 1-aryloxy-2-propanolamine and propylamine derivatives possessing class III antiarrhythmic activity
US20020061879A1 (en) * 1996-02-02 2002-05-23 Garvey David S. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
ATE554750T1 (de) 1997-03-05 2012-05-15 Sugen Inc Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungen
US6313294B1 (en) * 1998-02-04 2001-11-06 Development Center For Biotechnology Process for preparing amides
SV2002000205A (es) 1999-11-01 2002-06-07 Lilly Co Eli Compuestos farmaceuticos ref. x-01095
BR0015718A (pt) 1999-11-22 2002-07-23 Warner Lambert Co Quinazolinas e seu uso para inibição de enzimas de cinase dependente de ciclina
EP1110552A1 (en) 1999-12-22 2001-06-27 Aventis Pharma S.A. Use of a compound with affinity for the mitochondrial benzodiazepine receptor in cancer therapy
WO2001064646A2 (en) 2000-03-01 2001-09-07 Tularik Inc. Hydrazones and analogs as cholesterol lowering agents
CZ2003243A3 (cs) 2000-07-26 2003-09-17 Smithkline Beecham P. L. C. Aminopiperidinové chinoliny a jejich azaisosterické analogy s antibakteriální aktivitou
AUPR213700A0 (en) 2000-12-18 2001-01-25 Biota Scientific Management Pty Ltd Antiviral agents
MXPA03007166A (es) * 2001-02-12 2003-11-18 Hoffmann La Roche Pirido-pirimidinas 6-sustituidas.
US7875612B2 (en) 2001-04-24 2011-01-25 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
WO2002090360A1 (en) * 2001-05-10 2002-11-14 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
DE60316581T2 (de) * 2002-08-06 2008-07-03 F. Hoffmann-La Roche Ag 6-alkoxypyridopyrimidine als inhibitoren der p-38-map-kinase

Also Published As

Publication number Publication date
MXPA05010975A (es) 2005-11-28
CA2520785A1 (en) 2004-10-28
AR044515A1 (es) 2005-09-14
AU2004229163A1 (en) 2004-10-28
US20070135459A1 (en) 2007-06-14
CL2004000805A1 (es) 2005-02-04
TW200503722A (en) 2005-02-01
WO2004091625A1 (en) 2004-10-28
CN1774250A (zh) 2006-05-17
EP1620105B1 (en) 2007-01-10
ES2279361T3 (es) 2007-08-16
US7189731B2 (en) 2007-03-13
RU2005135329A (ru) 2006-08-10
JP2006523640A (ja) 2006-10-19
EP1620105A1 (en) 2006-02-01
DE602004004259D1 (de) 2007-02-22
DE602004004259T2 (de) 2007-11-15
US20040209903A1 (en) 2004-10-21
KR20060006037A (ko) 2006-01-18

Similar Documents

Publication Publication Date Title
DE60315146D1 (de) Heteroarylsubstituierte biphenylderivate als inhibitoren von p38-kinase
ATE517896T1 (de) P38-kinase-inhibitoren
ATE551059T1 (de) Fasudil in kombination mit bosentan zur behandlung von pulmonaler arterieller hypertonie
EA200600689A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов raf киназы
BR0112965A (pt) Derivados de 3-indolil-4-fenil-1h-pirrol-2,5-diona como inibidores de glocogênio sintase cinase-3beta
BR0313330A (pt) Piperidina-ftalazonas substituìdas com pirrolidinadiona como inibidores de pde4
ATE348616T1 (de) 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer
ATE353217T1 (de) 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren
CY1112947T1 (el) Παραγωγα πυρρολης καταλληλα για την θεραπεια πολλαπλασιαστικων ασθενειων
BRPI0409580A (pt) compostos de quinazolina
TW200714604A (en) Substituted heterocycles and the uses thereof
ATE413392T1 (de) Kondensierte heteroyralderivate und deren verwendung als p38-kinase-inhibitoren
BR0215360A (pt) Derivados de indolina úteis como inibidores de proteìna quinase
TW200740816A (en) P38 MAP kinase inhibitors and methods for using the same
DK1483251T3 (da) C3-cyano-epothilon-derivater
BRPI0416030A (pt) pirido-7-pirimidin-7-onas substituìdas com hidroxialquila
DE60219630D1 (de) Bicyclische pyrrolidinverbindungen
SE0302304D0 (sv) Novel compounds
BRPI0407913A (pt) antagonistas receptores de ccr-3
BRPI0409405A (pt) compostos 7-aza-quinazolina substituìdos
EA200701813A1 (ru) Новые амидозамещенные 6-фенилфенантридины
WO2005097755A3 (de) Imidazolderivate als hemmer von tyrosinkinase
DE60202669D1 (de) 6-phenylbenzonaphthyidine
ATE527264T1 (de) Kondensierte heterozyklische verbindungen als hemmer von proteinkinasen
ATE508130T1 (de) 3-oxa-10-aza-phenanthrene als pde4- oder pde3/4- inhibitoren

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired